Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Změní psilocybin synaptickou hustotu u amnestických mírných kognitivních poruch?

30. září 2026 aktualizováno: Philip Gerretsen, Centre for Addiction and Mental Health

Změní psilocybin synaptickou hustotu v mozcích pacientů s amnestickou mírnou kognitivní poruchou

The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants with amnestic Mild Cognitive Impairment (aMCI) and healthy participants. The investigators hypothesize that SVD levels in the brain will be higher following the ingestion of psilocybin in comparison to placebo, and that increases in SVD will be associated with improvements in cognition.

10 participants (6 with aMCI, and 4 sex and age matched healthy volunteers) will:

  • Be randomized to receive either:

    1. Two 25 mg macrodoses of psilocybin separated by 1 week.
    2. Two placebo doses separated by 1 week.
  • Receive a baseline 18F-SynVesT-1 PET scan, clinical, and neuropsychological assessments.

  • Receive a 18F-SynVesT-1 PET scan one week after the last dose of treatment.

  • Depending on available funds, receive a third PET scan at any time within 4 weeks of the screening visit to quantify tauopathy with the [18F]T807 radiotracer.

  • Receive clinical and neuropsychological testing 1, 4, and 12 weeks after the last treatment.

Researchers will compare placebo vs. experimental groups to see if psilocybin will increase SVD, and if increases in SVD are associated with cognitive improvements.

Přehled studie

Postavení

Dokončeno

Detailní popis

The proposed study will investigate the effects of on synaptic vesicular density (SVD) levels as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, and cognition (i.e., global cognition, executive function, and memory domains) in amnestic Mild Cognitive Impairment (aMCI) and healthy participants. Participants will be randomized to receive either two 25mg doses of psilocybin separated by one week, or two placebo doses separated by one week. Brain scans, clinical, and cognitive assessments will be conducted one week before, and one week, four weeks, and 12 weeks post dosing.

Typ studie

Intervenční

Zápis (Aktuální)

10

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Ontario
      • Toronto, Ontario, Kanada, M5T 1R8
        • Centre for Addiction and Mental Health

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

60 let až 75 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria

The aMCI participant must meet all of the inclusion criteria to be eligible for this clinical trial:

  1. Male or female participants of any race or ethnicity
  2. Inpatients or outpatients 60 to 75 years of age (on day of randomization)
  3. Diagnosis of MCI based on DSM 5 diagnostic criteria of Minor Neurocognitive Disorder
  4. Categorization of episodic memory impairment based on scores ≥ 1.0 SD lower on any of the following measures in comparison to normative data i. Logical Memory Test, ii. California Verbal Learning Test, iii. Brief Visual Memory Test
  5. Non-smoker/Non-nicotine user
  6. Montreal Cognitive Assessment (MoCA) score = < 26 and MMSE score > = 24
  7. Capable of consenting to participate in the research study
  8. On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
  9. Availability of a study partner who has regular contact with the participant
  10. Ability to read and communicate in English (with corrected vision and hearing, if needed)

The Healthy Control participant must meet all of the inclusion criteria to be eligible for this clinical trial:

  1. Male or female participants of any race or ethnicity
  2. 60 to 75 years of age (on day of randomization)
  3. Does not meet SCID-5 criteria for Mild Neurocognitive Disorder, Alzheimer's disease, or other major neurocognitive disorder
  4. Non-smoker/Non-nicotine user
  5. Capable of consenting to participate in the research study
  6. On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
  7. Availability of a study partner who has regular contact with the participant
  8. Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this clinical trial:

  1. Unwilling or incapable to consent to the study
  2. Unstable medical or any concomitant major medical or neurological illness, including presence of a relative or absolute contraindication to psilocybin, i.e. a drug allergy, recent stroke history, uncontrolled hypertension, low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment.
  3. History of head trauma resulting in loss of consciousness > 30 minutes that required medical attention.
  4. DSM-5 diagnosis, with active symptoms in the last three months, of major depression; lifetime diagnosis of bipolar disorder; intellectual disability; Alzheimer's Disease; or a psychotic disorder
  5. DSM-5 substance dependence (except caffeine) within 12 months of entering the study
  6. Anticonvulsant, antidepressant, antipsychotic, mood stabilizer, opioid, or benzodiazepine use
  7. Use of serotonergic psychedelic drugs within the past 10 years
  8. Positive urine drug screen at the screening visit
  9. Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks
  10. Acute suicidal or homicidal ideation
  11. Receiving treatment with medications such as levetiracetam that blocks SV2a binding, and/or inability to discontinue the following medications before study drug dosing: inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT)1A9 and (UGT)1A10, and ALDH inhibitors and alcohol dehydrogenase (ADH) inhibitors.
  12. Exceeding allowed annual radiation exposure levels (20 mSv), as outlined by our PET Centre guidelines
  13. Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans)
  14. Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (e.g., claustrophobia)
  15. Female with childbearing potential*, pregnancy (as confirmed by a negative pregnancy test) or breastfeeding
  16. Active gender affirming hormonal treatment
  17. Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I or II disorder as determined by the family medical history form and discussions with the participant.
  18. Allergies to hydroxypropyl methylcellulose *A woman/female or person who is not of childbearing potential is considered to be postmenopausal after at least 12 months without menstruation. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Females/people of childbearing potential are those who have experienced menarche and do not meet the criteria for women not of childbearing potential.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Jiný
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Amnestic Mild Cognitive Impairment Participants Receiving Psilocybin

Receiving 2 doses of 25mg of psilocybin separated by 1 week.

2 macrodoses of 25mg separated by one week.

Experimentální: Healthy Participants Receiving Psilocybin

Receiving 2 doses of 25mg of psilocybin separated by 1 week.

2 macrodoses of 25mg separated by one week.

Komparátor placeba: Amnestic Mild Cognitive Impairment Participants Receiving Placebo

Receiving 2 doses of placebo separated by 1 week.

2 doses of placebo separated by one week.

Komparátor placeba: Healthy Participants Receiving Placebo

Receiving 2 doses of placebo separated by 1 week.

2 doses of placebo separated by one week.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Synaptic Vesicular Density
Časové okno: 3 years

Synaptic vesicular density will be assessed with PET imaging by measuring the volume of distribution (i.e., defined as the ratio of the radioligand concentration in tissue target region (CT, kBq·cm-3) to that in plasma (CP, kBq·mL-1) at equilibrium) of the [18F]SynVesT-1 radioligand in the cortical and subcortical gray matter regions in the whole brain and more specifically, the hippocampus and dorsolateral prefrontal cortex.

3 years

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Global Cognition
Časové okno: 3 years

The results of the neuropsychological battery will be combined to a global cognition composite score as a Z-score, the change of which will be a secondary outcome measure. Z-scores will be comprised of the Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure, and will be calculated based on the performance of the equated comparison group. Each domain will contribute equally to the global cognition composite score.

3 years
Memory
Časové okno: 3 years

A memory composite Z-score will be generated using the performance on the following individual tests: Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score.

3 years
Executive Function
Časové okno: 3 years

An executive function composite Z-score will be generated using the performance on the following individual tests: Trail Making Test Part B, Wisconsin Card Sorting Test, Stroop Neuropsychological Screening, and the Executive Interview. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score.

3 years

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Exploratory Cognitive Outcomes
Časové okno: 3 years

If individual cognitive test scores are significantly different between groups, the mean difference of the individual test scores (i.e., Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure) will be analyzed separately as exploratory outcomes.

3 years
Exploratory Primary and Secondary Outcomes
Časové okno: 3 years

Primary and secondary outcomes will be compared between aMCI and healthy control groups.

The means of the primary outcome (i.e., volume of distribution) and secondary outcomes (i.e., cognitive composite Z-scores: global cognition, memory, and executive function) will be compared between aMCI and healthy control groups.

3 years

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Philip Gerretsen, MD, PhD, Centre for Addiction and Mental Health

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

27. listopadu 2023

Primární dokončení (Aktuální)

19. února 2026

Dokončení studie (Aktuální)

19. února 2026

Termíny zápisu do studia

První předloženo

1. srpna 2023

První předloženo, které splnilo kritéria kontroly kvality

14. září 2023

První zveřejněno (Aktuální)

18. září 2023

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

5. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

30. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit